DaVita/$DVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DaVita
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
Ticker
$DVA
Sector
Primary listing
NYSE
Industry
Health Care Providers and Services
Headquarters
Employees
76,000
Website
DaVita Metrics
BasicAdvanced
$11B
13.88
$10.11
1.14
-
Price and volume
Market cap
$11B
Beta
1.14
52-week high
$179.60
52-week low
$131.76
Average daily volume
804K
Financial strength
Current ratio
1.251
Quick ratio
1.125
Long term debt to equity
706.109
Total debt to equity
742.203
Interest coverage (TTM)
3.46%
Profitability
EBITDA (TTM)
2,659.368
Gross margin (TTM)
32.46%
Net profit margin (TTM)
6.63%
Operating margin (TTM)
15.01%
Effective tax rate (TTM)
18.55%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
7.04%
Return on equity (TTM)
54.79%
Valuation
Price to earnings (TTM)
13.882
Price to revenue (TTM)
0.897
Price to book
-40.61
Price to tangible book (TTM)
-1.38
Price to free cash flow (TTM)
6.614
Free cash flow yield (TTM)
15.12%
Free cash flow per share (TTM)
21.223
Growth
Revenue change (TTM)
5.11%
Earnings per share change (TTM)
14.90%
3-year revenue growth (CAGR)
3.74%
10-year revenue growth (CAGR)
-0.04%
3-year earnings per share growth (CAGR)
6.11%
10-year earnings per share growth (CAGR)
17.72%
What the Analysts think about DaVita
Analyst ratings (Buy, Hold, Sell) for DaVita stock.
Bulls say / Bears say
DaVita's expansion into Latin America, including Brazil and Colombia, is expected to drive future growth by tapping into new markets. (Nasdaq)
The company's strong financial performance, with adjusted operating income of $1.98 billion and adjusted EPS of $9.68 in 2024, demonstrates robust profitability. (TipRanks)
DaVita's commitment to returning capital to shareholders through share repurchases indicates confidence in its financial health and future prospects. (TipRanks)
DaVita faces a proposed class action lawsuit alleging anti-competitive practices that could lead to significant legal and financial repercussions. (Reuters)
The company's 2025 earnings guidance fell short of analyst expectations, projecting EPS between $10.20 and $11.30, below the consensus estimate of $11.24, raising concerns about future profitability. (The Motley Fool)
DaVita's treatment volume growth has consistently lagged behind internal expectations, with volume growth challenges persisting due to elevated mortality and mistreatment rates. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
DaVita Financial Performance
Revenues and expenses
DaVita Earnings Performance
Company profitability
DaVita News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DaVita stock?
DaVita (DVA) has a market cap of $11B as of August 01, 2025.
What is the P/E ratio for DaVita stock?
The price to earnings (P/E) ratio for DaVita (DVA) stock is 13.88 as of August 01, 2025.
Does DaVita stock pay dividends?
No, DaVita (DVA) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next DaVita dividend payment date?
DaVita (DVA) stock does not pay dividends to its shareholders.
What is the beta indicator for DaVita?
DaVita (DVA) has a beta rating of 1.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.